<bill session="115" type="h" number="6294" updated="2023-01-11T13:42:15Z">
  <state datetime="2018-06-28">REFERRED</state>
  <status>
    <introduced datetime="2018-06-28"/>
  </status>
  <introduced datetime="2018-06-28"/>
  <titles>
    <title type="display">REVAMP Act</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of priority antimicrobial products through the award of a transferable exclusivity extension period, and for other purposes.</title>
    <title type="short" as="introduced">Re-Valuing Anti-Microbial Products Act of 2018</title>
    <title type="short" as="introduced">REVAMP Act</title>
  </titles>
  <sponsor bioguide_id="S000364"/>
  <cosponsors>
    <cosponsor bioguide_id="C001097" joined="2018-06-28"/>
    <cosponsor bioguide_id="E000215" joined="2018-07-24"/>
  </cosponsors>
  <actions>
    <action datetime="2018-06-28">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-06-28" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Advisory bodies"/>
    <term name="Congressional oversight"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Government studies and investigations"/>
    <term name="Health promotion and preventive care"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Intellectual property"/>
    <term name="Licensing and registrations"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2019-08-20T18:49:34Z" status="Introduced in House">Re-Valuing Anti-Microbial Products Act of 2018 or the REVAMP Act

This bill amends the Federal Food, Drug, and Cosmetic Act to provide for an award of 12 additional months of market exclusivity to a drug manufacturer for a drug designated as a "priority antimicrobial product." (A priority antimicrobial product is intended to treat or prevent a disease attributable to a multi-drug resistant bacterial or fungal pathogen for which there is a critical unmet medical need.)</summary>
</bill>
